Gadodiamide, from Gadolinium, is often used in medical scans.

A July 2019 study by the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo found that, “…while a commonly used imaging linear contrast agent, gadodiamide, does accumulate in the brain early in the disease, there is no discernible clinical impact.” But that “At the same time, the study found that there were some indications of greater disease severity in patients who had undergone more magnetic resonance imaging (MRI) studies using these agents.”